Loading…
Xenon Pharmaceuticals Inc. is projected to rise to $62.58 by 2027, a +16% move from its current price of $53.90. XENE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $53.18 | $53.92 | $54.67 | +0.03% |
| May 30 | $52.89 | $53.94 | $55.00 | +0.07% |
| May 31 | $52.67 | $53.95 | $55.26 | +0.10% |
| Jun 1 | $52.49 | $53.97 | $55.49 | +0.13% |
| Jun 2 | $52.34 | $53.99 | $55.69 | +0.16% |
| Jun 3 | $52.20 | $54.01 | $55.87 | +0.20% |
| Jun 4 | $52.08 | $54.02 | $56.04 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $52.08 | $54.02 | $56.04 | +0.23% |
| Week 2 | $51.41 | $54.15 | $57.03 | +0.46% |
| Week 3 | $50.93 | $54.27 | $57.83 | +0.69% |
| Week 4 | $50.55 | $54.40 | $58.54 | +0.93% |
| Week 5 | $50.23 | $54.53 | $59.19 | +1.16% |
| Week 6 | $49.95 | $54.65 | $59.79 | +1.39% |
| Week 7 | $49.71 | $54.78 | $60.36 | +1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. (XENE) is currently trading at $54.17 per share. Its market capitalization stands at $5.24B, and the company holds a rank of 1311 in market listings.
The price outlook from the provided forecasts suggests upside beyond the near term, with the 2026 average at $54.17 and a 2030 average of $97.12. The long-range path shows continued upside through 2050, reaching an average of $410.30 with a max of $671.42 in 2050.
A major floor 25.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.4% away) — a key level to hold.
The nearest ceiling, 10.8% above — a clean break opens room to run.
A major ceiling 16.4% above — clearing it would confirm fresh momentum.
Key XENE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XENE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $54.17 | Sell | $54.12 | Sell |
| MA 10 | $54.49 | Sell | $54.50 | Sell |
| MA 20 | $55.49 | Sell | $55.07 | Sell |
| MA 50 | $56.09 | Sell | $54.39 | Sell |
| MA 100 | $50.07 | Buy | $51.35 | Buy |
| MA 200 | $45.26 | Buy | $47.00 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.49 | Neutral |
| Stoch RSI (14) | 16.27 | Buy |
| CCI (20) | -92.96 | Neutral |
| Williams %R (14) | -93.04 | Info |
| MACD (12,26,9) | -0.24 | Sell |
| ROC (12) | -4.50 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 6.96 | Buy |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | -2.04 | Sell |
| Ultimate (7,14,28) | 35.96 | Neutral |
| Momentum (10) | -1.10 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 53.94 | Sell |
| ADX (14) | 12.31 | Neutral |
| ATR (14) | 0.66 | Info |
The near-term technical picture is neutral, with RSI14 at 40 and sentiment labeled NEUTRAL.
The stock trades with a 30-day range from $49.16 to $59.69, and has a 50-day simple moving average of $56.13 compared with a 200-day average of $45.06. Support is at $53.71 and resistance at $59.70. Annualized volatility stands at 30%, signaling notable near-term variability between support and resistance levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $39.98 | $53.90 | $69.98 | 0% | Neutral | |
| $51.12 | $62.58 | $80.18 | +16% | Neutral | |
| $52.12 | $64.96 | $85.41 | +21% | Bullish | |
| $63.17 | $79.93 | $107.28 | +48% | Bullish | |
| $74.93 | $96.07 | $131.22 | +78% | Bullish | |
| $77.16 | $100.13 | $138.90 | +86% | Bullish | |
| $82.13 | $107.77 | $151.60 | +100% | Bullish | |
| $85.99 | $114.01 | $162.43 | +112% | Bullish | |
| $90.36 | $121.00 | $174.42 | +124% | Bullish | |
| $101.27 | $136.87 | $199.49 | +154% | Bullish | |
| $136.97 | $193.05 | $294.78 | +258% | Bullish | |
| $267.82 | $404.79 | $662.35 | +651% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $39.98 | $53.90 | $63.21 | +0.00% |
| June 2026 | $47.53 | $55.45 | $65.94 | +2.87% |
| July 2026 | $47.34 | $55.54 | $66.68 | +0.18% |
| August 2026 | $46.83 | $55.20 | $66.74 | -0.62% |
| September 2026 | $47.87 | $56.63 | $68.88 | +2.59% |
| October 2026 | $48.78 | $57.90 | $70.81 | +2.26% |
| November 2026 | $47.98 | $57.12 | $70.19 | -1.35% |
| December 2026 | $47.49 | $56.70 | $69.98 | -0.74% |
Click any year to see its month-by-month XENE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XENE to range from $39.98 to $69.98 through 2026. The $53.90 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The XENE price prediction for 2027 points to an average of $62.58 (low $51.12, high $80.18) — a potential gain of +16% on today's $53.90. Price action looks broadly range-bound.
In 2028, XENE is projected to trade between $52.12 and $85.41, averaging $64.96 — a potential gain of +21% from today's $53.90. That is up +4% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Xenon Pharmaceuticals Inc.'s 2029 outlook centres on $79.93, within a $63.17 to $107.28 range. That is up +23% on the projected 2028 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2030, XENE could reach as high as $131.22, with a base case around $96.07 and support toward $74.93 — roughly +78% from $53.90. Buyers look set to stay in control over this stretch.
Expect XENE to range from $77.16 to $138.90 through 2031. The $100.13 average target implies a +86% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The XENE price prediction for 2032 points to an average of $107.77 (low $82.13, high $151.60) — a potential gain of +100% on today's $53.90. Buyers look set to stay in control over this stretch.
In 2033, XENE is projected to trade between $85.99 and $162.43, averaging $114.01 — a potential gain of +112% from today's $53.90. That is up +6% on the projected 2032 average. Momentum favours further upside here.
Xenon Pharmaceuticals Inc.'s 2034 outlook centres on $121.00, within a $90.36 to $174.42 range. That is up +6% on the projected 2033 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, XENE could reach as high as $199.49, with a base case around $136.87 and support toward $101.27 — roughly +154% from $53.90. Momentum favours further upside here.
Expect XENE to range from $136.97 to $294.78 through 2040. The $193.05 average target implies a +258% move from current prices. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The XENE price prediction for 2050 points to an average of $404.79 (low $267.82, high $662.35) — a potential gain of +651% on today's $53.90. Momentum favours further upside here.
Investing $1,000 in XENE today (≈ 18.552876 XENE) could be worth
$7,510.02
+$6,510.02 (+651%) by 2050 · US Dollar
Based on the average projected XENE price of $404.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XENEwould be worth at today's price.
$1,000 invested in XENE on May 27, 2025 (≈ 33.944332 XENE) would be worth
$1,829.6
+$829.6 (+83.0%) today · 1.83× · US Dollar
Based on a XENE entry price of $29.46 vs. today's $53.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $54.68 | $985.74 | -1.4% |
| 1 month ago | $54.26 | $993.37 | -0.7% |
| 3 months ago | $44.92 | $1,199.91 | +20.0% |
| 6 months ago | $44.72 | $1,205.28 | +20.5% |
| 1 year ago | $29.46 | $1,829.6 | +83.0% |
| All time (5.0y) ago | $18.51 | $2,911.94 | +191.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XENE forecast.
Our base-case forecast reaches $110.00 around 2033.
Implied market cap at $110.00: $10.63B
The multi-year forecast shows gradual upside with notable strength in the later years. In 2026, the min is $39.98, the avg is $54.17, the max is $70.55, ROI 0, and sentiment NEUTRAL. In 2027, the avg is $63.08 with a max of $80.86 and ROI 16.4, sentiment NEUTRAL; 2028 yields an avg of $65.31 (max $85.89, ROI 20.6, sentiment BULLISH).
2029 shows an avg of $81.05 (max $108.81, ROI 49.6, sentiment BULLISH).
2030 projects an avg of $97.12 (max $132.68, ROI 79.3, sentiment BULLISH), with continued strength into 2031 (avg $100.47, max $139.40, ROI 85.5) and 2032 (avg $109.20, max $153.64, ROI 101.6). The trajectory remains bullish through 2033 (avg $115.44, max $164.50, ROI 113.1) and 2034 (avg $121.54, max $175.24, ROI 124.4), climbing to 2035 (avg $138.97, max $202.58, ROI 156.6).
Further out, 2040 shows an avg of $194.72 (max $297.35, ROI 259.5) and 2050 projects an avg of $410.30 (max $671.42, ROI 657.4), with bullish sentiment across these horizons. These figures reflect estimates, not guarantees, and are subject to market and development risks that can alter actual outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $97.12 and a high of $132.68, with a projected ROI of 79.3% and bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward, with rising averages and high potential in 2032 (max $153.64) and 2050 (max $671.42). However, these are estimates and not guarantees, and actual returns can vary.
Yes, the 2032 forecast lists a max of $153.64, which exceeds $150.
Current price is $54.17 per share, and market capitalization is $5.24B.
RSI14 is 40 with neutral sentiment. The 50-day SMA is $56.13, the 200-day SMA is $45.06, support is at $53.71, resistance at $59.70, and the 30-day price range is $49.16 to $59.69; annualized volatility is 30%.
Xenon Pharmaceuticals Inc. Community Discussion
0Share your Xenon Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.